Header Logo

Connection

JORGE CASTILLO to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications JORGE CASTILLO has written about Antineoplastic Agents.
JORGE CASTILLO
Connection Strength
5.281
Antineoplastic Agents
  1. Waldenstr?m Macroglobulinemia: Targeted Agents Taking Center Stage. Drugs. 2024 Jan; 84(1):17-25.
    View in: PubMed
    Score: 0.457
  2. Reducing treatment toxicity in Waldenstr?m macroglobulinemia. Expert Opin Drug Saf. 2021 Jun; 20(6):669-676.
    View in: PubMed
    Score: 0.378
  3. Ibrutinib Monotherapy in Symptomatic, Treatment-Na?ve Patients With Waldenstr?m Macroglobulinemia. J Clin Oncol. 2018 09 20; 36(27):2755-2761.
    View in: PubMed
    Score: 0.315
  4. Ibrutinib withdrawal symptoms in patients with Waldenstr?m macroglobulinemia. Haematologica. 2018 07; 103(7):e307-e310.
    View in: PubMed
    Score: 0.306
  5. Toward personalized treatment in Waldenstr?m macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):365-370.
    View in: PubMed
    Score: 0.302
  6. Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease. Leuk Res. 2017 11; 62:12-16.
    View in: PubMed
    Score: 0.297
  7. Plasma Cell Disorders. Prim Care. 2016 Dec; 43(4):677-691.
    View in: PubMed
    Score: 0.278
  8. Idelalisib in Waldenstr?m macroglobulinemia: high incidence of hepatotoxicity. Leuk Lymphoma. 2017 04; 58(4):1002-1004.
    View in: PubMed
    Score: 0.276
  9. Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy. AIDS. 2016 Mar 13; 30(5):787-96.
    View in: PubMed
    Score: 0.267
  10. Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. Cancer J. 2016 Jan-Feb; 22(1):34-9.
    View in: PubMed
    Score: 0.264
  11. CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options. Expert Rev Hematol. 2015 Jun; 8(3):343-54.
    View in: PubMed
    Score: 0.247
  12. Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia. Future Oncol. 2014 May; 10(7):1147-55.
    View in: PubMed
    Score: 0.235
  13. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2012 Jan; 21(1):15-22.
    View in: PubMed
    Score: 0.198
  14. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2011 Feb; 11(2):151-60.
    View in: PubMed
    Score: 0.188
  15. Current and emerging treatment perspectives for adults with Waldenstr?m macroglobulinemia. Expert Rev Anticancer Ther. 2025 May; 25(5):485-497.
    View in: PubMed
    Score: 0.125
  16. Venetoclax in Previously Treated Waldenstr?m Macroglobulinemia. J Clin Oncol. 2022 01 01; 40(1):63-71.
    View in: PubMed
    Score: 0.099
  17. Plasmablastic lymphoma transformation in a patient with Waldenstr?m macroglobulinemia treated with ibrutinib. Br J Haematol. 2021 11; 195(3):466-468.
    View in: PubMed
    Score: 0.097
  18. Consensus treatment recommendations from the tenth International Workshop for Waldenstr?m Macroglobulinaemia. Lancet Haematol. 2020 Nov; 7(11):e827-e837.
    View in: PubMed
    Score: 0.092
  19. CXCR4 mutations affect presentation and outcomes in patients with Waldenstr?m macroglobulinemia: A systematic review. Expert Rev Hematol. 2019 10; 12(10):873-881.
    View in: PubMed
    Score: 0.084
  20. Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenstr?m macroglobulinaemia on ibrutinib. Br J Haematol. 2019 05; 185(4):788-790.
    View in: PubMed
    Score: 0.081
  21. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. Br J Haematol. 2017 10; 179(2):339-341.
    View in: PubMed
    Score: 0.068
  22. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016 06 23; 127(25):3237-52.
    View in: PubMed
    Score: 0.067
  23. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016 06; 91(6):575-80.
    View in: PubMed
    Score: 0.067
  24. Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. Br J Haematol. 2017 06; 177(5):808-813.
    View in: PubMed
    Score: 0.067
  25. Central nervous system involvement by Waldenstr?m macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016 Mar; 172(5):709-15.
    View in: PubMed
    Score: 0.066
  26. Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base. Cancer Causes Control. 2015 Aug; 26(8):1163-72.
    View in: PubMed
    Score: 0.063
  27. The biology and treatment of plasmablastic lymphoma. Blood. 2015 Apr 09; 125(15):2323-30.
    View in: PubMed
    Score: 0.062
  28. Biology, prognosis, and therapy of Waldenstr?m Macroglobulinemia. Cancer Treat Res. 2015; 165:177-95.
    View in: PubMed
    Score: 0.062
  29. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2012 Mar; 21(3):355-61.
    View in: PubMed
    Score: 0.050
  30. Positive HIV ELISA test, autoimmune hemolytic anemia, and generalized lymphadenopathy: a unifying diagnosis. Am J Hematol. 2011 Aug; 86(8):690-3.
    View in: PubMed
    Score: 0.048
  31. Non-AIDS defining cancers. Med Health R I. 2010 Oct; 93(10):296-8.
    View in: PubMed
    Score: 0.046
  32. Extramedullary Waldenstr?m macroglobulinemia. Am J Hematol. 2015 Feb; 90(2):100-4.
    View in: PubMed
    Score: 0.015
  33. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. Am J Hematol. 2011 Aug; 86(8):663-7.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.